Cargando…
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Purpose: Despite high initial response rates with cytoreductive surgery, conventional chemotherapy and the incorporation of biologic agents, ovarian cancer patients often relapse and die from their disease. New approaches are needed to improve patient outcomes. This study was designed to evaluate th...
Autores principales: | Zeligs, Kristen P., Morelli, Maria Pia, David, Justin M., Neuman, Monica, Hernandez, Lidia, Hewitt, Stephen, Ozaki, Michelle, Osei-Tutu, Akosua, Anderson, David, Andresson, Thorkell, Das, Sudipto, Lack, Justin, Abdelmaksoud, Abdalla, Fantini, Massimo, Arlen, Philip M., Tsang, Kwong Y., Annunziata, Christina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318110/ https://www.ncbi.nlm.nih.gov/pubmed/32637350 http://dx.doi.org/10.3389/fonc.2020.00805 |
Ejemplares similares
-
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
por: Fantini, Massimo, et al.
Publicado: (2018) -
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
por: Tsang, Kwong Y., et al.
Publicado: (2022) -
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019) -
PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023) -
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
por: Cole, Christopher B., et al.
Publicado: (2023)